REQUESTING LIBRARY RECEIVING METHODS:

>>Ariel IP Address: 205.227.91.137<<
CENTRAL ARIEL PATRON NAME:
Odyssey IP Address:
MAIL: Knight Library, ILL Unit, 1299 University of Oregon, Eugene, OR 97403
FAX: 541-346-3094
EMAIL: libill@uoregon.edu

REQUEST ID: 27956

Mail  Electronic  Fax  Local  Pass: __________________________

Patron #: p1123080@ore0
PATRON DELIVERY PREFERENCE: Not Specified
Patron Note:

JOURNAL: Psychopharmacology
ARTICLE: Modification of visual orientation illusions by drugs which influence
AUTHOR: Gelbtuch, M H
YEAR: 1986
MONTH:
DAY:
QUARTER:
SEASON:
VOLUME: 90
ISSUE: 3
NUMBER:
PAGES: 379-83
PAGED LOCATIONS: >>za006<<, 9cubp
Staff Note:

LOCATION: MSU MAIN LIBRARY
CALL NUMBER: RC321 .P73
HOLDINGS: v.47 1976-v.184 2005
Modification of visual orientation illusions by drugs which influence dopamine and GABA neurones: Differential effects on simultaneous and successive illusions

M.H. Gelbthuch, J.E. Calvert, J.P. Harris, and O.T. Phillipson
Brain and Perception Laboratory, Anatomy Department, Medical School, University Walk, Bristol BS8 1TD, UK

Abstract. The effects of haloperidol, nomifensine and lorazepam on the visual tilt illusion were studied in normal volunteers. Haloperidol and nomifensine produced no significant changes in the illusion, although in previous work they had been found to reduce and enhance, respectively, a closely related illusion, the tilt aftereffect. By contrast, lorazepam produced a dose-related increment in the size of the tilt illusion, but had no effect on the tilt aftereffect. The results are discussed in relation to proposed mechanisms which may underlie the two kinds of illusion. The differential effects of individual drugs on the two illusions may reflect their differing actions on two processes: lateral inhibition and adaptation in visual channels.

Key words: Haloperidol — Nomifensine — Lorazepam — Visual tilt illusion — GABA — Dopamine

There is ample evidence that in acute schizophrenia, an illness in which a malfunction of brain dopaminergic mechanisms has been heavily implicated (see Crow et al. 1976 for review) various relatively simple aspects of perception are abnormal. Such evidence comes from the reports of patients themselves (e.g. Chapman 1966; Phillipson and Harris 1985) as well as more objective studies (see, e.g. McGhie 1977 for review). To complement such studies of patients, we have begun to examine the effects of drugs which are known to affect dopaminergic transmission on visual perception in healthy volunteers. Two commonly studied visual effects — the movement and tilt aftereffect (Anstis 1975; Braddock et al. 1978; Frisby 1979) — are perceptual distortions of motion and orientation. The tilt aftereffect (TAE) is the apparent tilt of a line or grating which follows prolonged inspection of a line or grating in a slightly different orientation. The movement aftereffect (MAE) is the apparent motion of a stationary field which follows inspection of a moving field. It has been reported that the MAE is abnormally long in schizophrenia (Abraham and McCallum 1973; Claridge 1967). We have found that the neuroleptic drugs chlorpromazine and haloperidol reduce both the movement and the tilt aftereffects, while the antidepressant nomifensine, which potentiates dopaminergic transmission by preventing the re-uptake of dopamine, enhances the tilt aftereffect (Harris et al. 1983, 1986).

How might the drugs produce these changes? One explanation for the TAE is that it results from the effects of prolonged lateral inhibition in the visual cortex (Tolhurst and Thompson 1975). Thus, during inspection of the adapting stripes, inhibition from the most excited orientation detector is supposed to produce a short-lived reduction in the output of detectors which prefer neighbouring orientations. When the subject subsequently inspects the test stripes, the detectors giving the greatest output may not be those whose preferred orientation corresponds to the physical orientation of the test grating, and so a shift in apparent tilt occurs. So, we speculated, one possible effect of the drugs might be to change the strength of lateral inhibition in the visual cortex. If this speculation is correct, then the simultaneous tilt illusion (TI) should also be affected by appropriate drug treatment. In this illusion (Blakemore et al. 1970), the apparent tilts of lines whose orientation and position are similar are distorted. Figure 1 gives an example, in which the central circular patches of grating are vertical and parallel to each other, but have opposite apparent tilts induced by their surrounding stripes. The distortion is a perceptual expansion of small acute angles. It has been suggested that both this effect and the tilt aftereffect result from lateral inhibition between orientation selective channels in the visual cortex (Tolhurst and Thompson 1975).

It is likely that lateral inhibitory tuning in the visual cortex, where orientation-selective neurons are first encountered in the visual system, is mediated by GABA. This neurotransmitter has a putative inhibitory role in visual cortex (Iversen et al. 1971), and bicuculline, a GABA antagonist, has been shown to reduce or even remove the orientation selectivity of cortical neurones (Sillito 1979). It is plausible to assume that this occurs because bicuculline reduces the inhibitory input to the cell from other orientation-sensitive neurons whose preferred orientation is slightly different.

With these considerations in mind, we have measured the effects of drugs which affect dopaminergic transmission on the TI, and of lorazepam, a benzodiazepine which potentiates the activity of GABA (see Tallman and Gallager 1985 for review), on both the TI and two aftereffects, the TAE and the MAE.

Method

Apparatus and procedure

The tilt illusion. The illusion was measured on a circular area of grating 2.7° in diameter. Immediately surrounding
One of the gratings. A block of five settings to vertical was made on the test grating with the adapting grating covered. Then two blocks of five adapting trials were run, in which the subject scanned along a horizontal bar in the middle of the adapting grating (with the test grating covered) then adjusted the test grating to appear vertical while gazing at its centre (with the adapting grating covered). Settings were disturbed between trials. In one block, adaptation lasted for 30 s, in the other for 40 s. The time taken from the end of adaptation to make each setting was measured with a stop clock.

Movement aftereffect. The apparatus and procedure have been described elsewhere (Harris et al. 1983). A 5° 38 min diameter rotatable (5 rpm) field of small circular dots (10 min) was back-projected on a Perspex screen. Surrounding this field was a 11° square area of random texture. Viewing distance was 183 cm. Two blocks of five tests were made, one of 30 s, the other of 40 s adaptation. The subject gazed at the centre of the display, the movement was turned on for the appropriate time, then turned off, and the reported duration of the MAE timed with a stop-clock.

Drowsiness and simple reaction time. Subjective estimates of drowsiness were made on analog scales. The data for haloperidol, nomifensine and maprotiline have been reported elsewhere (Harris et al. 1986). For lorazepam, the subject was asked to place a mark corresponding to his present state of alertness on a 16 mm long straight line. One end of the line was designated "hyperalert", the other "barely awake", and the mid-point "normal for time of day". To measure RT's, the subject gazed at a small red LED, and had the press a push-button as soon as possible after the LED was illuminated. A microcomputer measured the interval between LED illumination and response to the nearest millisecond. Again, the data from haloperidol, nomifensine and maprotiline have been reported elsewhere (Harris et al. 1986). For lorazepam, two blocks of ten RT measures, one at the beginning and one at the end of the test session were run.

Drugs

Haloperidol was given by mouth at a dose of 0.05 mg/kg. This results in plasma concentrations of drug in the range 2–4 ng/ml serum (Forsman and Ohman 1974). Since peak plasma concentrations are found 3–6 h after oral dosage, the drug was given at 11.00 hours and testing began at 14.00 hours. It was compared with inert placebo in 14 normal healthy volunteers (nine male, five female), age range 19–34 years, in a repeated measures design. On their first visit to the laboratory, half the subjects received placebo, half haloperidol. At least 6 clear days were left between successive experimental days, except for three subjects for whom the interval was 3 days, and two subjects for whom it was 2 days.

Oral nomifensine was given at 12.00 hours at a dose of 50 mg, 2 h before testing. This regime has been reported by others to yield peak plasma concentrations in the range 93–177 ng/ml (Brogden et al. 1979).

Nomifensine blocks reuptake both of noradrenaline and dopamine. To control for effects of this drug on noradrenergic uptake sites, parallel tests were done using maprotiline which, at low concentrations, acts highly specifically against
noradrenaline uptake sites in rat brain (Brogden et al. 1979). Maprotiline was given as an oral dose of 50 mg at 09.00 hours, and testing began at 14.00–16.00 hours, a time when plasma concentrations are rising rapidly. Peak concentrations of this drug are not attained until about 10 h after administration.

Nomifensine and maprotiline were compared with each other and with placebo in 15 normal subjects, (ten male, 18–22 years), in a repeated measures experiment. The order of drug administration was randomised over subjects. At least 6 days occurred between administration of different drugs, except for one subject for whom it was 5 days; for three subjects, 4 days; and for one subject, 2 days.

Lorazepam was given by mouth at 0.015 or 0.030 mg/kg 1 h before testing, at a time when peak plasma concentrations may be achieved (Dundee et al. 1978). These two doses were compared with each other and with placebo in 12 subjects (all male, 19–24 years), in a repeated measures design. The minimum interval between successive experimental days was at least 5 clear days, except for four subjects, for whom one interval was 2 days.

The subjects were almost all students, mostly of medical sciences, who were paid for their participation, and informed about the broad aims of the study. Perceptual and other tests were done double-blind.

Results

For the TI, each setting made with the masking annulus in position was subtracted from the corresponding setting with the inducing stripes visible. Each pre-adaptation setting on the TAE display was subtracted from the corresponding post-adaptation setting. These five difference scores were treated as measures of the TI and TAE, respectively, and the means calculated for each block. The results from the TAE and MAE for the neuroleptics chlorpromazine and haloperidol, and the antidepressant nomifensine have been reported elsewhere (Harris et al. 1983, 1986). The TI results for haloperidol and the antidepressant are shown in Fig. 2. Haloperidol tended to enhance the illusion, but the effect was not significant: (t = 1.59; df = 13; P > 0.05). The mean tilt illusions for placebo and maprotiline were almost identical, and although nomifensine tended to reduce the illusion compared with maprotiline and placebo, the effects were not significant (from the drug (3) by subject (15) analysis of variance, F = 1.29; df = 2.28; P > 0.05). These findings contrast with the corresponding results on the tilt aftereffect found in earlier experiments. Thus, haloperidol significantly reduced both tilt and movement aftereffects, while nomifensine significantly enhanced the tilt aftereffect (Harris et al. 1986).

The effects of lorazepam on all three visual tests are shown in Fig. 3. There was a clear enhancement of the TI, with a dose-dependent effect, 0.015 mg/kg giving a larger effect than placebo and smaller than the 0.030 mg/kg dose. From the drug (3) by subject (12) Analysis of Variance this effect was significant (F = 4.40; df = 2.22; P < 0.025). Although the F ratios reflect the consistency of the effects, one can ask, for example, how many subjects produced results in the opposite direction to the means. For the tilt illusion, after lorazepam, (which gave a significant enhancement) only 2/12 produced an illusion after the high dose of drug which was smaller than that after placebo. For haloperidol, (which gave no significant enhancement of the TI) 6/14 gave a smaller TI after haloperidol than placebo, with one subject giving identical illusions in the two drug conditions. For the anti-depressants (when no significant changes were found), 7/15 subjects gave a larger tilt illusion after nomifensine than after placebo and 7/15 for nomifensine compared with maprotiline.

In contrast to the tilt illusion, lorazepam had little effect on the TAE from the drug (3) by adapting time (2) by subject (12) ANOVA, for the drug effect, F = 0.12; df = 2.22; P > 0.05; and for the adapting time effect, F = 0.108; df = 1.11; P > 0.05). The small increase in response times to set the TAE test grating to appear vertical was not significant (from the ANOVA, F = 2.54; df = 2.22; P > 0.05), so that it is unlikely that any drug effect on the TAE was nullified by greater decay of the aftereffect. There was a small enhancement of the MAE by the drug, but this was not significant [from the drug (3) by adapting time (2) by subject (12) ANOVA, F = 2.05; df = 2.22; P > 0.05], and was not related to dosage in the same way as the TI result. A significant effect of adapting time was found for the MAE, the longer adapting time giving significantly longer aftereffects (F = 16.21; df = 1.11; P > 0.01). The consistency of the measurements reflected this lack of significance. Averaged over the two adaptation durations, 6/12 subjects gave a smaller TAE after the high dose of lorazepam than after placebo, and 5/12 a shorter MAE after the high dose of lorazepam than after placebo.
Lorazepam increased subjective drowsiness. (The values given are the mean displacement from the midpoint of the scale, and a minus means a change towards greater drowsiness.) For the placebo condition, the shift (in cm) was −0.57 (sd 1.08), for the low dose −1.24 (1.25), and for the high dose −4.11 (1.87). The ANOVA showed that the drug effect was significant ($F = 28.23; df = 2,22; P < 0.001$). The reaction time data showed a trend consistent with the drowsiness estimates: for the placebo condition, mean RT ($\pm sd$) was 222.4 ms (5.9), for the low dose 225.4 (5.8) and for the high dose 234.6 (6.8). However, the effect was not significant (from the ANOVA, $F = 1.22; df = 2,22; P > 0.05$).

Discussion

The present experiments show that the tilt illusion is unaffected by either dopaminergic agonist or antagonist drugs within the dose ranges chosen. These results are in contrast to earlier work (Harris et al. 1983, 1986) in which we found that dopamine agonists increase and antagonists decrease the tilt aftereffect. On the other hand, the tilt illusion is increased by lorazepam, a drug which potentiates GABA-mediated neurotransmission, in a dose-dependent fashion. The tilt aftereffect was, by contrast, unaffected by lorazepam.

Some potential artefacts

It is interesting that despite their similar effects in increasing subjective drowsiness, the neuroleptics and the benzodiazepine have different effects on visual processes. This suggests that the visual effects are not simply a concomitant of the effects on alertness. Additional evidence against simple drowsiness effects underlying the results was obtained with maprotiline. Compared to lorazepam, subjective drowsiness ratings after maprotiline were similar. However, only lorazepam caused a change in the tilt illusion. It is clear, therefore, that the presence of drowsiness does not predict drug-induced changes in either the tilt illusion or the tilt aftereffect.

It might be argued that our failure to find significant changes in the TI with, say, haloperidol and in the TAE with lorazepam arose from some failure in techniques, which were not sensitive enough to detect drug-induced changes in perception. However, the findings that the techniques detect perceptual changes with other drugs, and that the drugs induce changes on other tests are evidence against this view.

In interpreting the results, we assume that similar processes underlie the tilt and motion aftereffects, even though they may operate on different neural channels. In general, this assumption is justified by the data, which suggest that the two aftereffects are similarly affected by the various drugs we have studied. An exception to this rule are the effects of nomifensine which enhances the TAE, but not the MAE, though the trends in the MAE data are similar (Harris et al. 1986). Our procedure for measuring the MAE does not allow us to distinguish between changes in neural adaptation and changes in criterion for the end of apparent motion (see Harris et al. 1986 for further discussion of these points). If nomifensine affected both of these, it might lead to the obtained result. Certainly, this result cannot be used to argue for different processes underlying the MAE and TAE.

Neural processing and the mechanism of the illusions

How might the dissociation between the perceptual effects arise? There is an important difference between the procedures for obtaining TAEs and TIs which might lead to drugs (or other variations) having differential effects on the two illusions. This is the prolonged inspection of the adapting grating alone which is necessary to obtain the TAE. In the TI, both gratings are present simultaneously, and long inspection periods are not required. If we accept that lateral inhibition underlies both the TAE and TI, and follow Wallace (1975) in the simple assumptions that the lateral inhibition produced by a neuron is proportional to its excitation and that excitation and inhibition add linearly, then any manipulation which reduced excitation during adaptation (leaving excitation by the briefly viewed test grating relatively unaffected) would reduce the TAE. However, such a manipulation would not affect the TI, since the neurons responding to the "inducing" and "test" gratings would be equally affected and the relative strengths of their excitation and mutual inhibition would be unchanged. On the other hand, a manipulation which affected cortical lateral inhibition alone would affect both the TAE and the TI in the same way. Finally, a manipulation which changed the strength of excitation in one direction and of inhibition in the other direction would affect the TI, but its effects on the TAE would depend on the relative amounts of change in excitation and inhibition.

The physiological evidence strongly suggests that lateral inhibitory interactions which underlie orientation selectivity in the visual cortex are mediated by a GABA neuron (Silitto 1979; Somogyi et al. 1983). Thus the simplest explanation for the enhancement of the tilt illusion by lorazepam is an increase in lateral inhibition between cortical orientation detectors. However, the finding that the TAE and MAE are scarcely affected by lorazepam suggests that, if lateral inhibition underlies them, the drug may have more complicated effects, since if its sole effect were on cortical lateral inhibition then the aftereffects as well as the illusion would be affected. One possibility is that the drug reduces excitation in visual channels, as well as enhancing inhibition between them. If the lateral inhibition exerted by a neuron is proportional to its excitation (as assumed for a related illusion by Wallace 1975) then the potentially greater lateral inhibition during the adapting period of the TAE and MAE could be nullified by the reduction in excitation, so that little net change in aftereffect would occur. The finding (Harris and Phillipson, in preparation) that lorazepam reduces contrast sensitivity and threshold elevation for similar gratings displays is consistent with this view.

Turning to the drugs which change dopaminergic activity, in summary we find that dopamine receptor blockers reduce the aftereffects, and nomifensine enhances the TAE (Harris et al. 1986), but have no significant effects on the tilt illusion. It is clear that one of our earlier suggestions, that the blockers reduce the TAE and MAE by reducing lateral inhibition in the cortex, is not supported. If this were the case then one would expect that the tilt illusion would also be reduced, but this was not found. Indeed, though insignificant, the tendency was for the drugs to have the opposite effect on the tilt illusion to that on the tilt.
aftereffect. To follow the line of reasoning put forward to account for the lorazepam effect, these results suggest that this second class of drug changes excitation in visual channels rather than lateral inhibition between them. One result of this alteration may be an associated change in adaptation. The functional nature of the postulated change of excitation produced by the drugs cannot be further specified from the present evidence. Among the possibilities are a lowering of sensitivity across the entire contrast range, or a change of supra-threshold gain with no effects on absolute threshold. These questions are now under investigation by measuring contrast thresholds before and after adaptation to high contrast gratings, following administration of drugs.

Though speculative at present, the idea that the contrast gain of selectively activated visual channels may be reduced by neuroleptics, and thus involve dopaminergic mechanisms, is an attractive one. For example, a commonly reported symptom of schizophrenia is a change in brightness contrast (see, e.g. Chapman 1966). In a questionnaire study (Phillipson and Harris 1985), we found that, in a sample of 45 patients who reported visual distortions, abnormalities of brightness contrast were the most common symptom. Since changes in luminance contrast are known to influence the perception of other visual properties such as velocity (Thompson 1982; Harris 1982) or colour (Trosclair 1977) and to influence the size of the TAE (Parker 1972) the hypothesis that disorders of gain control (subjectively, a change of contrast) may underlie some visual distortions of schizophrenia seems worth pursuing further.

Acknowledgements. We thank the MRC for support, and our subjects for their cooperation. Permission for the study was given by the Bristol and Weston Health District Ethical Committee.

References


Sillito AM (1979) Inhibitory mechanisms influencing complex cell orientation selectivity and their modification at high resting discharge levels. J Physiol 289:33-53


Trosclair TS (1977) Effect of subliminal and surround luminance on the perception of a coloured field. Colour Research and Application 2:153-159


Received October 18, 1985; final version April 29, 1986